Novo Nordisk Hit By Diabetes Drug Delay; Sanofi RisesShares of Novo Nordisk fell 14% and Sanofi rose 3.2% on Monday, a day after Novo announced that its challenger to Sanofi's leading drug has hit a roadblock. The Food and Drug Administration said it won't approve Novo's (NVO) long-acting insulin candidate degludec until it gets more data assessing the possible heart risks associated with the drug. This was a surprise since the FDA went beyond the recommendations that its advisory panel made in
Source:
Novo Nordisk Hit By Diabetes Drug Delay; Sanofi RisesLinkback:
https://tubagbohol.mikeligalig.com/index.php?topic=68698.0